Infant Bacterial Therapeutics AB Stock

Equities

IBT B

SE0008015259

Pharmaceuticals

Real-time Estimate Cboe Europe 04:35:21 2024-04-26 am EDT 5-day change 1st Jan Change
86.5 SEK -1.03% Intraday chart for Infant Bacterial Therapeutics AB +4.03% -2.44%
Sales 2022 - Sales 2023 0.08 0.84 Capitalization 1.21B 13.18B
Net income 2022 -65M -707M Net income 2023 -123M -1.34B EV / Sales 2022 -
Net cash position 2022 336M 3.65B Net cash position 2023 329M 3.58B EV / Sales 2023 11,472,257,143 x
P/E ratio 2022
-8.58 x
P/E ratio 2023
-9.04 x
Employees 8
Yield 2022 *
-
Yield 2023
-
Free-Float 88.04%
More Fundamentals * Assessed data
Dynamic Chart
Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Infant Bacterial Therapeutics AB Announces the Appointment of the Nomination Committee for the Annual General Meeting 2024 CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sweden’s Infant Bacterial Therapeutics to Raise SEK101 Million via Rights Issue MT
Infant Bacterial Therapeutics AB Announces Data Monitoring Committee Performs the Planned Safety Analysis of the Study Data of 1,403 Babies CI
Infant Bacterial Therapeutics AB Continues to Recruit Precious to Its Connection Study CI
Infant Bacterial Therapeutics AB Announces New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Infant Bacterial Therapeutics Announces Opening of Final Infant Cohort Will Accelerate Patient Recruitment CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Infant Bacterial Therapeutics AB Publishes Clinical Findings in British Journal of Gastroenterology CI
Infant Bacterial Therapeutics AB Secures Platform for Pharma Grade Probiotic to Prevent Antibiotic Resistant Hospital Acquired Infections CI
More news
1 day-1.03%
1 week+4.03%
Current month+9.75%
1 month+15.83%
3 months-12.20%
6 months+4.03%
Current year-2.44%
More quotes
1 week
83.00
Extreme 83
89.40
1 month
74.20
Extreme 74.2
89.80
Current year
70.80
Extreme 70.8
107.00
1 year
41.30
Extreme 41.3
107.00
3 years
41.30
Extreme 41.3
122.40
5 years
41.30
Extreme 41.3
274.50
10 years
32.70
Extreme 32.7
274.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 12-12-31
Director of Finance/CFO 51 22-09-18
Chief Operating Officer 57 14-10-19
Members of the board TitleAgeSince
Director/Board Member 58 15-09-23
Chairman 74 10-12-31
Director/Board Member 44 17-05-03
More insiders
Date Price Change Volume
24-04-26 87.8 +0.46% 25
24-04-25 87.4 -0.46% 914
24-04-24 87.8 +2.09% 8,502
24-04-23 86 -1.38% 1,551
24-04-22 87.2 +3.32% 1,142

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 03:24 am EDT

More quotes
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Calendar
More about the company